MapLight Therapeutics, Inc.
ML-004
autism spectrum disorder
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ML-004 for autism spectrum disorder around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“Following a full review of the data, the Company expects to engage with the FDA in an EOP2 meeting to determine the future development path”